{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:07:55Z","timestamp":1793858875958,"version":"4.6.1"},"reference-count":285,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41577-021-00634-8","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T05:03:39Z","timestamp":1636520619000},"page":"411-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":160,"title":["Crosstalk between the renin\u2013angiotensin, complement and kallikrein\u2013kinin systems in inflammation"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5942-281X","authenticated-orcid":false,"given":"Zivile","family":"Bekassy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Lopatko Fagerstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-7658","authenticated-orcid":false,"given":"Diana","family":"Karpman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"634_CR1","doi-asserted-by":"crossref","first-page":"H958","DOI":"10.1152\/ajpheart.00723.2018","volume":"316","author":"RAS Santos","year":"2019","unstructured":"Santos, R. A. S. et al. The renin-angiotensin system: going beyond the classical paradigms. Am. J. Physiol. Heart Circ. Physiol. 316, H958\u2013H970 (2019).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"634_CR2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","volume":"33","author":"M Noris","year":"2013","unstructured":"Noris, M. & Remuzzi, G. Overview of complement activation and regulation. Semin. Nephrol. 33, 479\u2013492 (2013).","journal-title":"Semin. Nephrol."},{"key":"634_CR3","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1182\/blood.V90.10.3819","volume":"90","author":"RW Colman","year":"1997","unstructured":"Colman, R. W. & Schmaier, A. H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90, 3819\u20133843 (1997). This is a seminal review of the contact system.","journal-title":"Blood"},{"key":"634_CR4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","volume":"98","author":"SJ Forrester","year":"2018","unstructured":"Forrester, S. J. et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol. Rev. 98, 1627\u20131738 (2018).","journal-title":"Physiol. Rev."},{"key":"634_CR5","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","volume":"309","author":"F Li","year":"2005","unstructured":"Li, F., Li, W., Farzan, M. & Harrison, S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864\u20131868 (2005).","journal-title":"Science"},{"key":"634_CR6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e278 (2020).","journal-title":"Cell"},{"key":"634_CR7","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.cell.2021.02.053","volume":"184","author":"ML Yeung","year":"2021","unstructured":"Yeung, M. L. et al. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell 184, 2212\u20132228.e12 (2021).","journal-title":"Cell"},{"key":"634_CR8","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue, M. et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139. Circ. Res. 87, E1\u2013E9 (2000).","journal-title":"Circ. Res."},{"key":"634_CR9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631\u2013637 (2004).","journal-title":"J. Pathol."},{"key":"634_CR10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112\u2013116 (2005). This study demonstrates the role of the canonical pathway in severe lung injury and the protective role of ACE2.","journal-title":"Nature"},{"key":"634_CR11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875\u2013879 (2005). This study provides evidence for ACE2 as the receptor for the SARS-CoV spike protein.","journal-title":"Nat. Med."},{"key":"634_CR12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1055\/s-0040-1712960","volume":"46","author":"S de Maat","year":"2020","unstructured":"de Maat, S., de Mast, Q., Danser, A. H. J., van de Veerdonk, F. L. & Maas, C. Impaired breakdown of bradykinin and its metabolites as a possible cause for pulmonary edema in COVID-19 infection. Semin. Thromb. Hemost. 46, 835\u2013837 (2020).","journal-title":"Semin. Thromb. Hemost."},{"key":"634_CR13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","volume":"66","author":"VB Patel","year":"2014","unstructured":"Patel, V. B. et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: a positive feedback mechanism in the RAS. J. Mol. Cell Cardiol. 66, 167\u2013176 (2014).","journal-title":"J. Mol. Cell Cardiol."},{"key":"634_CR14","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","volume":"118","author":"VB Patel","year":"2016","unstructured":"Patel, V. B., Zhong, J. C., Grant, M. B. & Oudit, G. Y. Role of the ACE2\/angiotensin 1\u20137 axis of the renin-angiotensin system in heart failure. Circ. Res. 118, 1313\u20131326 (2016).","journal-title":"Circ. Res."},{"key":"634_CR15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/HYPERTENSIONAHA.117.10357","volume":"71","author":"B Neubauer","year":"2018","unstructured":"Neubauer, B. et al. Angiotensin II short-loop feedback: is there a role of Ang II for the regulation of the renin system in vivo? Hypertension 71, 1075\u20131082 (2018).","journal-title":"Hypertension"},{"key":"634_CR16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/HYPERTENSIONAHA.117.09379","volume":"70","author":"M Bader","year":"2017","unstructured":"Bader, M. Of mice and renin. Hypertension 70, 35\u201337 (2017).","journal-title":"Hypertension"},{"key":"634_CR17","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1097\/01.ASN.0000146686.35541.29","volume":"15","author":"M Azizi","year":"2004","unstructured":"Azizi, M. et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. 15, 3126\u20133133 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"634_CR18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2012.249","volume":"9","author":"B Sev\u00e1 Pess\u00f4a","year":"2013","unstructured":"Sev\u00e1 Pess\u00f4a, B. et al. Key developments in renin-angiotensin-aldosterone system inhibition. Nat. Rev. Nephrol. 9, 26\u201336 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"634_CR19","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/HYPERTENSIONAHA.116.08118","volume":"68","author":"S Galandrin","year":"2016","unstructured":"Galandrin, S. et al. Cardioprotective angiotensin-(1\u20137) peptide acts as a natural-biased ligand at the angiotensin II type 1 receptor. Hypertension 68, 1365\u20131374 (2016).","journal-title":"Hypertension"},{"key":"634_CR20","doi-asserted-by":"crossref","first-page":"39721","DOI":"10.1074\/jbc.M105253200","volume":"276","author":"S AbdAlla","year":"2001","unstructured":"AbdAlla, S., Lother, H., Abdel-tawab, A. M. & Quitterer, U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J. Biol. Chem. 276, 39721\u201339726 (2001).","journal-title":"J. Biol. Chem."},{"key":"634_CR21","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/HYPERTENSIONAHA.116.08814","volume":"69","author":"J Leonhardt","year":"2017","unstructured":"Leonhardt, J. et al. Evidence for heterodimerization and functional interaction of the angiotensin type 2 receptor and the receptor MAS. Hypertension 69, 1128\u20131135 (2017).","journal-title":"Hypertension"},{"key":"634_CR22","doi-asserted-by":"crossref","first-page":"aad1210","DOI":"10.1126\/science.aad1210","volume":"352","author":"G Arbore","year":"2016","unstructured":"Arbore, G. et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells. Science 352, aad1210 (2016).","journal-title":"Science"},{"key":"634_CR23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1084\/jem.179.6.1809","volume":"179","author":"B Ghebrehiwet","year":"1994","unstructured":"Ghebrehiwet, B., Lim, B. L., Peerschke, E. I., Willis, A. C. & Reid, K. B. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular \u201cheads\u201d of C1q. J. Exp. Med. 179, 1809\u20131821 (1994).","journal-title":"J. Exp. Med."},{"key":"634_CR24","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.molimm.2010.05.009","volume":"47","author":"EI Peerschke","year":"2010","unstructured":"Peerschke, E. I., Yin, W. & Ghebrehiwet, B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol. Immunol. 47, 2170\u20132175 (2010).","journal-title":"Mol. Immunol."},{"key":"634_CR25","doi-asserted-by":"crossref","first-page":"26739","DOI":"10.1074\/jbc.271.43.26739","volume":"271","author":"BL Lim","year":"1996","unstructured":"Lim, B. L. et al. The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor. J. Biol. Chem. 271, 26739\u201326744 (1996).","journal-title":"J. Biol. Chem."},{"key":"634_CR26","doi-asserted-by":"crossref","first-page":"101338","DOI":"10.1016\/j.smim.2019.101338","volume":"45","author":"B Ghebrehiwet","year":"2019","unstructured":"Ghebrehiwet, B., Geisbrecht, B. V., Xu, X., Savitt, A. G. & Peerschke, E. I. B. The C1q receptors: focus on gC1qR\/p33 (C1qBP, p32, HABP-1)(1). Semin. Immunol. 45, 101338 (2019).","journal-title":"Semin. Immunol."},{"key":"634_CR27","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.molimm.2006.11.012","volume":"44","author":"W Yin","year":"2007","unstructured":"Yin, W., Ghebrehiwet, B., Weksler, B. & Peerschke, E. I. Classical pathway complement activation on human endothelial cells. Mol. Immunol. 44, 2228\u20132234 (2007).","journal-title":"Mol. Immunol."},{"key":"634_CR28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12468","volume":"274","author":"P Garred","year":"2016","unstructured":"Garred, P. et al. A journey through the lectin pathway of complement-MBL and beyond. Immunol. Rev. 274, 74\u201397 (2016).","journal-title":"Immunol. Rev."},{"key":"634_CR29","volume":"7","author":"K Hess","year":"2012","unstructured":"Hess, K. et al. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS ONE 7, e35690 (2012).","journal-title":"PLoS ONE"},{"key":"634_CR30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000623","volume":"2","author":"A Krarup","year":"2007","unstructured":"Krarup, A., Wallis, R., Presanis, J. S., G\u00e1l, P. & Sim, R. B. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2, e623 (2007).","journal-title":"PLoS ONE"},{"key":"634_CR31","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4049\/jimmunol.1102916","volume":"188","author":"LR La Bonte","year":"2012","unstructured":"La Bonte, L. R. et al. Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J. Immunol. 188, 885\u2013891 (2012).","journal-title":"J. Immunol."},{"key":"634_CR32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-3083.1996.d01-298.x","volume":"44","author":"EW Nielsen","year":"1996","unstructured":"Nielsen, E. W. et al. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand. J. Immunol. 44, 185\u2013192 (1996).","journal-title":"Scand. J. Immunol."},{"key":"634_CR33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020036","volume":"6","author":"J Dob\u00f3","year":"2011","unstructured":"Dob\u00f3, J. et al. Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS ONE 6, e20036 (2011).","journal-title":"PLoS ONE"},{"key":"634_CR34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3389\/fimmu.2019.00991","volume":"10","author":"ML Debreczeni","year":"2019","unstructured":"Debreczeni, M. L. et al. MASP-1 increases endothelial permeability. Front. Immunol. 10, 991 (2019).","journal-title":"Front. Immunol."},{"key":"634_CR35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.129.2.315","volume":"129","author":"OD Ratnoff","year":"1969","unstructured":"Ratnoff, O. D., Pensky, J., Ogston, D. & Naff, G. B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C\u20191r subcomponent of the first component of complement by serum C\u20191 esterase inhibitor. J. Exp. Med. 129, 315\u2013331 (1969).","journal-title":"J. Exp. Med."},{"key":"634_CR36","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1016\/S0021-9258(18)89258-4","volume":"260","author":"PC Harpel","year":"1985","unstructured":"Harpel, P. C., Lewin, M. F. & Kaplan, A. P. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J. Biol. Chem. 260, 4257\u20134263 (1985).","journal-title":"J. Biol. Chem."},{"key":"634_CR37","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.molimm.2010.05.010","volume":"47","author":"AP Kaplan","year":"2010","unstructured":"Kaplan, A. P. & Ghebrehiwet, B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol. Immunol. 47, 2161\u20132169 (2010).","journal-title":"Mol. Immunol."},{"key":"634_CR38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/01.CIR.94.3.517","volume":"94","author":"AA Hasan","year":"1996","unstructured":"Hasan, A. A., Amenta, S. & Schmaier, A. H. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 94, 517\u2013528 (1996).","journal-title":"Circulation"},{"key":"634_CR39","first-page":"1","volume":"44","author":"KD Bhoola","year":"1992","unstructured":"Bhoola, K. D., Figueroa, C. D. & Worthy, K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44, 1\u201380 (1992).","journal-title":"Pharmacol. Rev."},{"key":"634_CR40","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.biochi.2015.09.023","volume":"122","author":"M Kalinska","year":"2016","unstructured":"Kalinska, M., Meyer-Hoffert, U., Kantyka, T. & Potempa, J. Kallikreins - the melting pot of activity and function. Biochimie 122, 270\u2013282 (2016).","journal-title":"Biochimie"},{"key":"634_CR41","doi-asserted-by":"crossref","first-page":"17962","DOI":"10.1074\/jbc.M106101200","volume":"277","author":"Z Shariat-Madar","year":"2002","unstructured":"Shariat-Madar, Z., Mahdi, F. & Schmaier, A. H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 277, 17962\u201317969 (2002).","journal-title":"J. Biol. Chem."},{"key":"634_CR42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1073\/pnas.022626899","volume":"99","author":"K Joseph","year":"2002","unstructured":"Joseph, K., Tholanikunnel, B. G. & Kaplan, A. P. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc. Natl Acad. Sci. USA 99, 896\u2013900 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR43","doi-asserted-by":"crossref","first-page":"33688","DOI":"10.1074\/jbc.M000313200","volume":"275","author":"T Renn\u00e9","year":"2000","unstructured":"Renn\u00e9, T., Dedio, J., David, G. & M\u00fcller-Esterl, W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J. Biol. Chem. 275, 33688\u201333696 (2000).","journal-title":"J. Biol. Chem."},{"key":"634_CR44","doi-asserted-by":"crossref","first-page":"16621","DOI":"10.1074\/jbc.M313850200","volume":"279","author":"F Mahdi","year":"2004","unstructured":"Mahdi, F. et al. Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor. J. Biol. Chem. 279, 16621\u201316628 (2004).","journal-title":"J. Biol. Chem."},{"key":"634_CR45","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1073\/pnas.93.16.8552","volume":"93","author":"K Joseph","year":"1996","unstructured":"Joseph, K., Ghebrehiwet, B., Peerschke, E. I., Reid, K. B. & Kaplan, A. P. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular \u201cheads\u201d of C1q (gC1q-R). Proc. Natl Acad. Sci. USA 93, 8552\u20138557 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1160\/TH03-07-0471","volume":"91","author":"K Joseph","year":"2004","unstructured":"Joseph, K., Tholanikunnel, B. G., Ghebrehiwet, B. & Kaplan, A. P. Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb. Haemost. 91, 61\u201370 (2004).","journal-title":"Thromb. Haemost."},{"key":"634_CR47","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-569111","volume":"131","author":"C Maas","year":"2018","unstructured":"Maas, C. & Renn\u00e9, T. Coagulation factor XII in thrombosis and inflammation. Blood 131, 1903\u20131909 (2018).","journal-title":"Blood"},{"key":"634_CR48","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.cell.2009.11.001","volume":"139","author":"F M\u00fcller","year":"2009","unstructured":"M\u00fcller, F. et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139, 1143\u20131156 (2009).","journal-title":"Cell"},{"key":"634_CR49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0166-2236(93)90133-7","volume":"16","author":"A Dray","year":"1993","unstructured":"Dray, A. & Perkins, M. Bradykinin and inflammatory pain. Trends Neurosci. 16, 99\u2013104 (1993).","journal-title":"Trends Neurosci."},{"key":"634_CR50","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1172\/JCI0215490","volume":"109","author":"AH Schmaier","year":"2002","unstructured":"Schmaier, A. H. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J. Clin. Invest. 109, 1007\u20131009 (2002).","journal-title":"J. Clin. Invest."},{"key":"634_CR51","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1189\/jlb.1103546","volume":"75","author":"M Stuardo","year":"2004","unstructured":"Stuardo, M. et al. Stimulated human neutrophils form biologically active kinin peptides from high and low molecular weight kininogens. J. Leukoc. Biol. 75, 631\u2013640 (2004).","journal-title":"J. Leukoc. Biol."},{"key":"634_CR52","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.4049\/jimmunol.0803624","volume":"182","author":"R Kahn","year":"2009","unstructured":"Kahn, R. et al. Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin. J. Immunol. 182, 7906\u20137915 (2009). This work shows that neutrophil-derived proteinase 3 cleaves high-molecular-weight kininogen, generating a vasoactive peptide, PR3-kinin, that binds to B1R, and this pathway circumvents kallikrein-mediated kinin release.","journal-title":"J. Immunol."},{"key":"634_CR53","first-page":"1","volume":"32","author":"D Regoli","year":"1980","unstructured":"Regoli, D. & Barab\u00e9, J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32, 1\u201346 (1980).","journal-title":"Pharmacol. Rev."},{"key":"634_CR54","doi-asserted-by":"crossref","first-page":"106305","DOI":"10.1016\/j.intimp.2020.106305","volume":"82","author":"F Marceau","year":"2020","unstructured":"Marceau, F. et al. Bradykinin receptors: agonists, antagonists, expression, signaling, and adaptation to sustained stimulation. Int. Immunopharmacol. 82, 106305 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"634_CR55","first-page":"447","volume":"120b","author":"PG Matthews","year":"1979","unstructured":"Matthews, P. G. & Johnston, C. I. Responses of the renin-angiotensin system and kallikrein-kinin system to sodium and converting enzyme inhibitor (SQ 14,225). Adv. Exp. Med. Biol. 120b, 447\u2013457 (1979).","journal-title":"Adv. Exp. Med. Biol."},{"key":"634_CR56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.npep.2009.12.004","volume":"44","author":"F Kuhr","year":"2010","unstructured":"Kuhr, F., Lowry, J., Zhang, Y., Brovkovych, V. & Skidgel, R. A. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides 44, 145\u2013154 (2010).","journal-title":"Neuropeptides"},{"key":"634_CR57","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/FJC.0b013e31828165db","volume":"61","author":"WB Campbell","year":"2013","unstructured":"Campbell, W. B. & Gauthier, K. M. Inducible endothelium-derived hyperpolarizing factor: role of the 15-lipoxygenase-EDHF pathway. J. Cardiovasc. Pharmacol. 61, 176\u2013187 (2013).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"634_CR58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.peptides.2012.07.020","volume":"37","author":"FL Basei","year":"2012","unstructured":"Basei, F. L. et al. Endothelium dependent expression and underlying mechanisms of des-Arg9-bradykinin-induced B1R-mediated vasoconstriction in rat portal vein. Peptides 37, 216\u2013224 (2012).","journal-title":"Peptides"},{"key":"634_CR59","doi-asserted-by":"crossref","first-page":"C267","DOI":"10.1152\/ajpcell.00138.2011","volume":"302","author":"C Bodor","year":"2012","unstructured":"Bodor, C. et al. Angiotensin II increases the permeability and PV-1 expression of endothelial cells. Am. J. Physiol. Cell Physiol. 302, C267\u2013C276 (2012).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"634_CR60","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.HYP.25.5.913","volume":"25","author":"B Williams","year":"1995","unstructured":"Williams, B., Baker, A. Q., Gallacher, B. & Lodwick, D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25, 913\u2013917 (1995).","journal-title":"Hypertension"},{"key":"634_CR61","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0196-9781(99)00123-0","volume":"20","author":"MA Oliveira","year":"1999","unstructured":"Oliveira, M. A., Fortes, Z. B., Santos, R. A., Kosla, M. C. & De Carvalho, M. H. Synergistic effect of angiotensin-(1\u20137) on bradykinin arteriolar dilation in vivo. Peptides 20, 1195\u20131201 (1999).","journal-title":"Peptides"},{"key":"634_CR62","first-page":"403","volume":"286","author":"G Gorelik","year":"1998","unstructured":"Gorelik, G., Carbini, L. A. & Scicli, A. G. Angiotensin 1\u20137 induces bradykinin-mediated relaxation in porcine coronary artery. J. Pharmacol. Exp. Ther. 286, 403\u2013410 (1998).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"634_CR63","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1172\/JCI7886","volume":"104","author":"Y Tsutsumi","year":"1999","unstructured":"Tsutsumi, Y. et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J. Clin. Invest. 104, 925\u2013935 (1999).","journal-title":"J. Clin. Invest."},{"key":"634_CR64","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.bjp.0704731","volume":"136","author":"J Katada","year":"2002","unstructured":"Katada, J. & Majima, M. AT2 receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br. J. Pharmacol. 136, 484\u2013491 (2002).","journal-title":"Br. J. Pharmacol."},{"key":"634_CR65","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1161\/01.HYP.33.5.1237","volume":"33","author":"HM Siragy","year":"1999","unstructured":"Siragy, H. M. & Carey, R. M. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 33, 1237\u20131242 (1999). This study shows that in Ang II-mediated hypertension, AT2R counter-regulates blood pressure elevation via the renal bradykinin\u2013NO\u2013cGMP pathway.","journal-title":"Hypertension"},{"key":"634_CR66","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCRESAHA.115.304110","volume":"115","author":"BA Kemp","year":"2014","unstructured":"Kemp, B. A. et al. AT2 receptor activation induces natriuresis and lowers blood pressure. Circ. Res. 115, 388\u2013399 (2014).","journal-title":"Circ. Res."},{"key":"634_CR67","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12016-016-8561-8","volume":"51","author":"BL Zuraw","year":"2016","unstructured":"Zuraw, B. L. & Christiansen, S. C. HAE pathophysiology and underlying mechanisms. Clin. Rev. Allergy Immunol. 51, 216\u2013229 (2016).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"634_CR68","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1096\/fj.02-0737com","volume":"17","author":"T Monsinjon","year":"2003","unstructured":"Monsinjon, T. et al. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 17, 1003\u20131014 (2003).","journal-title":"FASEB J."},{"key":"634_CR69","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.1900371","volume":"202","author":"XX Li","year":"2019","unstructured":"Li, X. X., Lee, J. D., Kemper, C. & Woodruff, T. M. The complement receptor C5aR2: a powerful modulator of innate and adaptive immunity. J. Immunol. 202, 3339\u20133348 (2019).","journal-title":"J. Immunol."},{"key":"634_CR70","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1269","volume":"4","author":"PA Ward","year":"2004","unstructured":"Ward, P. A. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4, 133\u2013142 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"634_CR71","volume":"13","author":"F Wu","year":"2016","unstructured":"Wu, F. et al. Complement component C3a plays a critical role in endothelial activation and leukocyte recruitment into the brain. J. Neuroinflammation 13, 23 (2016).","journal-title":"J. Neuroinflammation"},{"key":"634_CR72","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.4049\/jimmunol.169.4.2102","volume":"169","author":"IU Schraufstatter","year":"2002","unstructured":"Schraufstatter, I. U., Trieu, K., Sikora, L., Sriramarao, P. & DiScipio, R. Complement C3a and C5a induce different signal transduction cascades in endothelial cells. J. Immunol. 169, 2102\u20132110 (2002).","journal-title":"J. Immunol."},{"key":"634_CR73","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood-2010-01-264051","volume":"116","author":"I Kourtzelis","year":"2010","unstructured":"Kourtzelis, I. et al. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 116, 631\u2013639 (2010).","journal-title":"Blood"},{"key":"634_CR74","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/1523-1747.ep12480568","volume":"97","author":"HW Lim","year":"1991","unstructured":"Lim, H. W., He, D., Esquenazi-Behar, S., Yancey, K. B. & Soter, N. A. C5a, cutaneous mast cells, and inflammation: in vitro and in vivo studies in a murine model. J. Invest. Dermatol. 97, 305\u2013311 (1991).","journal-title":"J. Invest. Dermatol."},{"key":"634_CR75","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav5951","volume":"4","author":"Y Miyabe","year":"2019","unstructured":"Miyabe, Y., Miyabe, C., Mani, V., Mempel, T. R. & Luster, A. D. Atypical complement receptor C5aR2 transports C5a to initiate neutrophil adhesion and inflammation. Sci. Immunol. 4, eaav5951 (2019).","journal-title":"Sci. Immunol."},{"key":"634_CR76","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/1873-3468.13881","volume":"594","author":"TE Mollnes","year":"2020","unstructured":"Mollnes, T. E. & Huber-Lang, M. Complement in sepsis-when science meets clinics. FEBS Lett. 594, 2621\u20132632 (2020).","journal-title":"FEBS Lett."},{"key":"634_CR77","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.4049\/jimmunol.1302417","volume":"193","author":"V Schmitz","year":"2014","unstructured":"Schmitz, V. et al. C5a and bradykinin receptor cross-talk regulates innate and adaptive immunity in Trypanosoma cruzi infection. J. Immunol. 193, 3613\u20133623 (2014).","journal-title":"J. Immunol."},{"key":"634_CR78","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/BF01704710","volume":"20","author":"W N\u00fcrnberger","year":"1994","unstructured":"N\u00fcrnberger, W., Petrik, K., Burdach, S. & G\u00f6bel, U. C1 esterase inhibitor (C1-INH) can reduce plasma concentrations of the complement activation product C5a. Intensive Care Med. 20, 242 (1994).","journal-title":"Intensive Care Med."},{"key":"634_CR79","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.4049\/jimmunol.173.11.6921","volume":"173","author":"F Bossi","year":"2004","unstructured":"Bossi, F. et al. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J. Immunol. 173, 6921\u20136927 (2004). This work shows that both bradykinin and soluble C5b-9 induced vascular permeability and that the effect of soluble C5b-9 was inhibited by a B2R antagonist and a kallikrein inhibitor.","journal-title":"J. Immunol."},{"key":"634_CR80","volume":"15","author":"K Bork","year":"2020","unstructured":"Bork, K. et al. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J. Rare Dis. 15, 289 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"634_CR81","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12016-021-08836-7","volume":"60","author":"AE Germenis","year":"2021","unstructured":"Germenis, A. E., Rijavec, M. & Veronez, C. L. Leveraging genetics for hereditary angioedema: a road map to precision medicine. Clin. Rev. Allergy Immunol. 60, 416\u2013428 (2021).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"634_CR82","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0091-6749(83)90052-0","volume":"72","author":"T Fields","year":"1983","unstructured":"Fields, T., Ghebrehiwet, B. & Kaplan, A. P. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of \u201cspontaneous\u201d formation of bradykinin. J. Allergy Clin. Immunol. 72, 54\u201360 (1983).","journal-title":"J. Allergy Clin. Immunol."},{"key":"634_CR83","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/jth.14209","volume":"16","author":"S De Maat","year":"2018","unstructured":"De Maat, S., Hofman, Z. L. M. & Maas, C. Hereditary angioedema: the plasma contact system out of control. J. Thromb. Haemost. 16, 1674\u20131685 (2018).","journal-title":"J. Thromb. Haemost."},{"key":"634_CR84","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","volume":"351","author":"J Nussberger","year":"1998","unstructured":"Nussberger, J. et al. Plasma bradykinin in angio-oedema. Lancet 351, 1693\u20131697 (1998).","journal-title":"Lancet"},{"key":"634_CR85","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jaci.2010.08.012","volume":"126","author":"AP Kaplan","year":"2010","unstructured":"Kaplan, A. P. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J. Allergy Clin. Immunol. 126, 918\u2013925 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"634_CR86","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2146\/ajhp110227","volume":"69","author":"JL Martello","year":"2012","unstructured":"Martello, J. L., Woytowish, M. R. & Chambers, H. Ecallantide for treatment of acute attacks of hereditary angioedema. Am. J. Health Syst. Pharm. 69, 651\u2013657 (2012).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"634_CR87","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s40265-019-01206-w","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed, Y. Y. Lanadelumab: a review in hereditary angioedema. Drugs 79, 1777\u20131784 (2019).","journal-title":"Drugs"},{"key":"634_CR88","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1716995","volume":"379","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2018","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn, E. et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. N. Engl. J. Med. 379, 352\u2013362 (2018).","journal-title":"N. Engl. J. Med."},{"key":"634_CR89","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/emmm.201000080","volume":"2","author":"A Benigni","year":"2010","unstructured":"Benigni, A., Cassis, P. & Remuzzi, G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol. Med. 2, 247\u2013257 (2010).","journal-title":"EMBO Mol. Med."},{"key":"634_CR90","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.exger.2019.02.012","volume":"119","author":"R Li","year":"2019","unstructured":"Li, R. et al. Long-term stimulation of angiotensin II induced endothelial senescence and dysfunction. Exp. Gerontol. 119, 212\u2013220 (2019).","journal-title":"Exp. Gerontol."},{"key":"634_CR91","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0002-9440(10)64445-8","volume":"161","author":"DN Muller","year":"2002","unstructured":"Muller, D. N. et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am. J. Pathol. 161, 1679\u20131693 (2002).","journal-title":"Am. J. Pathol."},{"key":"634_CR92","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"RAS Santos","year":"2018","unstructured":"Santos, R. A. S. et al. The ACE2\/angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1\u20137). Physiol. Rev. 98, 505\u2013553 (2018). This is a comprehensive review of the protective effects of the non-canonical pathway of the RAS in tissues.","journal-title":"Physiol. Rev."},{"key":"634_CR93","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bcp.2018.08.045","volume":"156","author":"L Gonzalez","year":"2018","unstructured":"Gonzalez, L. et al. Angiotensin-(1\u20139) reduces cardiovascular and renal inflammation in experimental renin-independent hypertension. Biochem. Pharmacol. 156, 357\u2013370 (2018).","journal-title":"Biochem. Pharmacol."},{"key":"634_CR94","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1161\/01.HYP.38.1.95","volume":"38","author":"B Tom","year":"2001","unstructured":"Tom, B., de Vries, R., Saxena, P. R. & Danser, A. H. Bradykinin potentiation by angiotensin-(1\u20137) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension 38, 95\u201399 (2001).","journal-title":"Hypertension"},{"key":"634_CR95","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.110.167346","volume":"57","author":"FD Marques","year":"2011","unstructured":"Marques, F. D. et al. An oral formulation of angiotensin-(1\u20137) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 57, 477\u2013483 (2011).","journal-title":"Hypertension"},{"key":"634_CR96","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/01.HYP.0000017283.67962.02","volume":"39","author":"HL Jackman","year":"2002","unstructured":"Jackman, H. L. et al. Angiotensin 1\u20139 and 1\u20137 release in human heart: role of cathepsin A. Hypertension 39, 976\u2013981 (2002).","journal-title":"Hypertension"},{"key":"634_CR97","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1161\/01.HYP.33.3.835","volume":"33","author":"B Marcic","year":"1999","unstructured":"Marcic, B., Deddish, P. A., Jackman, H. L. & Erd\u00f6s, E. G. Enhancement of bradykinin and resensitization of its B2 receptor. Hypertension 33, 835\u2013843 (1999).","journal-title":"Hypertension"},{"key":"634_CR98","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1096\/fj.01-0641com","volume":"16","author":"T Walther","year":"2002","unstructured":"Walther, T. et al. AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats. FASEB J. 16, 1237\u20131241 (2002).","journal-title":"FASEB J."},{"key":"634_CR99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.phrs.2017.07.008","volume":"125","author":"E Kaschina","year":"2017","unstructured":"Kaschina, E., Namsolleck, P. & Unger, T. AT2 receptors in cardiovascular and renal diseases. Pharmacol. Res. 125, 39\u201347 (2017).","journal-title":"Pharmacol. Res."},{"key":"634_CR100","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0735-1097(98)00441-0","volume":"32","author":"A Jalowy","year":"1998","unstructured":"Jalowy, A., Schulz, R., D\u00f6rge, H., Behrends, M. & Heusch, G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J. Am. Coll. Cardiol. 32, 1787\u20131796 (1998).","journal-title":"J. Am. Coll. Cardiol."},{"key":"634_CR101","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/hh1001.090759","volume":"88","author":"XP Yang","year":"2001","unstructured":"Yang, X. P. et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ. Res. 88, 1072\u20131079 (2001).","journal-title":"Circ. Res."},{"key":"634_CR102","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1006\/bbrc.1999.0500","volume":"258","author":"M Tanaka","year":"1999","unstructured":"Tanaka, M. et al. Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 knockout mice. Biochem. Biophys. Res. Commun. 258, 194\u2013198 (1999).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"634_CR103","doi-asserted-by":"crossref","first-page":"2401081","DOI":"10.1155\/2019\/2401081","volume":"2019","author":"M de Carvalho Santuchi","year":"2019","unstructured":"de Carvalho Santuchi, M. et al. Angiotensin-(1\u20137) and alamandine promote anti-inflammatory response in macrophages in vitro and in vivo. Mediators Inflamm. 2019, 2401081 (2019).","journal-title":"Mediators Inflamm."},{"key":"634_CR104","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1124\/pr.118.017129","volume":"71","author":"LB Arendse","year":"2019","unstructured":"Arendse, L. B. et al. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol. Rev. 71, 539\u2013570 (2019).","journal-title":"Pharmacol. Rev."},{"key":"634_CR105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","volume":"17","author":"M Paz Ocaranza","year":"2020","unstructured":"Paz Ocaranza, M. et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat. Rev. Cardiol. 17, 116\u2013129 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"634_CR106","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon, S. D. et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609\u20131620 (2019).","journal-title":"N. Engl. J. Med."},{"key":"634_CR107","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","volume":"52","author":"M Haschke","year":"2013","unstructured":"Haschke, M. et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52, 783\u2013792 (2013).","journal-title":"Clin. Pharmacokinet."},{"key":"634_CR108","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrendo.2015.6","volume":"11","author":"CA Romero","year":"2015","unstructured":"Romero, C. A., Orias, M. & Weir, M. R. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat. Rev. Endocrinol. 11, 242\u2013252 (2015).","journal-title":"Nat. Rev. Endocrinol."},{"key":"634_CR109","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/ATVBAHA.113.303120","volume":"34","author":"C Zhang","year":"2014","unstructured":"Zhang, C. et al. Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling. Arterioscler. Thromb. Vasc. Biol. 34, 1240\u20131248 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"634_CR110","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/CIRCRESAHA.117.312153","volume":"122","author":"XH Chen","year":"2018","unstructured":"Chen, X. H. et al. Deficiency of complement C3a and C5a receptors prevents angiotensin II-induced hypertension via regulatory T cells. Circ. Res. 122, 970\u2013983 (2018).","journal-title":"Circ. Res."},{"key":"634_CR111","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.kint.2018.04.004","volume":"94","author":"ZD B\u00e9k\u00e1ssy","year":"2018","unstructured":"B\u00e9k\u00e1ssy, Z. D. et al. Aliskiren inhibits renin-mediated complement activation. Kidney Int. 94, 689\u2013700 (2018). This work demonstrates for the first time that C3 is a renin substrate and that renin inhibition had a beneficial effect in complement-mediated renal disease.","journal-title":"Kidney Int."},{"key":"634_CR112","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.1195821","volume":"330","author":"F Forneris","year":"2010","unstructured":"Forneris, F. et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330, 1816\u20131820 (2010).","journal-title":"Science"},{"key":"634_CR113","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0022-3476(79)80282-6","volume":"95","author":"KG Gerdts","year":"1979","unstructured":"Gerdts, K. G., Shah, V., Savage, J. M. & Dillon, M. J. Renal vein renin measurements in normotensive children. J. Pediatr. 95, 953\u2013958 (1979).","journal-title":"J. Pediatr."},{"key":"634_CR114","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/01.RES.0000182677.89816.38","volume":"97","author":"E Shagdarsuren","year":"2005","unstructured":"Shagdarsuren, E. et al. Complement activation in angiotensin II-induced organ damage. Circ. Res. 97, 716\u2013724 (2005).","journal-title":"Circ. Res."},{"key":"634_CR115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","volume":"15","author":"RJH Smith","year":"2019","unstructured":"Smith, R. J. H. et al. C3 glomerulopathy \u2014 understanding a rare complement-driven renal disease. Nat. Rev. Nephrol. 15, 129\u2013143 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"634_CR116","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3389\/fimmu.2020.01079","volume":"11","author":"M Schattner","year":"2020","unstructured":"Schattner, M., Jenne, C. N., Negrotto, S. & Ho-Tin-Noe, B. Editorial: platelets and immune responses during thromboinflammation. Front. Immunol. 11, 1079 (2020).","journal-title":"Front. Immunol."},{"key":"634_CR117","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/imr.12471","volume":"274","author":"KN Ekdahl","year":"2016","unstructured":"Ekdahl, K. N. et al. Dangerous liaisons: complement, coagulation, and kallikrein\/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol. Rev. 274, 245\u2013269 (2016).","journal-title":"Immunol. Rev."},{"key":"634_CR118","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ana.24380","volume":"77","author":"E G\u00f6b","year":"2015","unstructured":"G\u00f6b, E. et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. Ann. Neurol. 77, 784\u2013803 (2015).","journal-title":"Ann. Neurol."},{"key":"634_CR119","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1172\/JCI92880","volume":"128","author":"EX Stavrou","year":"2018","unstructured":"Stavrou, E. X. et al. Factor XII and uPAR upregulate neutrophil functions to influence wound healing. J. Clin. Invest. 128, 944\u2013959 (2018).","journal-title":"J. Clin. Invest."},{"key":"634_CR120","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/rth2.12235","volume":"3","author":"AH Schmaier","year":"2019","unstructured":"Schmaier, A. H. & Stavrou, E. X. Factor XII \u2014 what\u2019s important but not commonly thought about. Res. Pract. Thromb. Haemost. 3, 599\u2013606 (2019).","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"634_CR121","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3389\/fimmu.2019.02011","volume":"10","author":"T Renn\u00e9","year":"2019","unstructured":"Renn\u00e9, T. & Stavrou, E. X. Roles of factor XII in innate immunity. Front. Immunol. 10, 2011 (2019).","journal-title":"Front. Immunol."},{"key":"634_CR122","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2015-01-622811","volume":"126","author":"KF Nickel","year":"2015","unstructured":"Nickel, K. F. et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 126, 1379\u20131389 (2015).","journal-title":"Blood"},{"key":"634_CR123","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2014-01-550285","volume":"125","author":"EX Stavrou","year":"2015","unstructured":"Stavrou, E. X. et al. Reduced thrombosis in Klkb1\u2212\/\u2212 mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood 125, 710\u2013719 (2015). This study shows a novel mechanism of kallikrein-mediated thrombosis whereby its decrease increases expression of the receptor MAS.","journal-title":"Blood"},{"key":"634_CR124","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.thromres.2016.02.020","volume":"140","author":"Y Kokoye","year":"2016","unstructured":"Kokoye, Y. et al. A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. Thromb. Res. 140, 118\u2013124 (2016).","journal-title":"Thromb. Res."},{"key":"634_CR125","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1182\/blood-2012-09-459156","volume":"121","author":"C Fang","year":"2013","unstructured":"Fang, C. et al. Angiotensin 1\u20137 and Mas decrease thrombosis in Bdkrb2\u2212\/\u2212 mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood 121, 3023\u20133032 (2013).","journal-title":"Blood"},{"key":"634_CR126","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1182\/blood-2007-06-092338","volume":"111","author":"S Merkulov","year":"2008","unstructured":"Merkulov, S. et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 111, 1274\u20131281 (2008).","journal-title":"Blood"},{"key":"634_CR127","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1073\/pnas.74.10.4636","volume":"74","author":"RC Wiggins","year":"1977","unstructured":"Wiggins, R. C., Bouma, B. N., Cochrane, C. G. & Griffin, J. H. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation factor XI and prekallikrein. Proc. Natl Acad. Sci. USA 74, 4636\u20134640 (1977).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR128","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1073\/pnas.76.10.4862","volume":"76","author":"RE Thompson","year":"1979","unstructured":"Thompson, R. E., Mandle, R. Jr & Kaplan, A. P. Studies of binding of prekallikrein and factor XI to high molecular weight kininogen and its light chain. Proc. Natl Acad. Sci. USA 76, 4862\u20134866 (1979).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/STROKEAHA.108.526673","volume":"40","author":"M Austinat","year":"2009","unstructured":"Austinat, M. et al. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 40, 285\u2013293 (2009).","journal-title":"Stroke"},{"key":"634_CR130","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/jcbfm.2010.28","volume":"30","author":"F Raslan","year":"2010","unstructured":"Raslan, F. et al. Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation. J. Cereb. Blood Flow. Metab. 30, 1477\u20131486 (2010).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"634_CR131","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17648-w","volume":"11","author":"J Wilbs","year":"2020","unstructured":"Wilbs, J. et al. Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs. Nat. Commun. 11, 3890 (2020).","journal-title":"Nat. Commun."},{"key":"634_CR132","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1055\/s-0039-1692439","volume":"45","author":"EP DeLoughery","year":"2019","unstructured":"DeLoughery, E. P., Olson, S. R., Puy, C., McCarty, O. J. T. & Shatzel, J. J. The safety and efficacy of novel agents targeting factors XI and XII in early phase human trials. Semin. Thromb. Hemost. 45, 502\u2013508 (2019).","journal-title":"Semin. Thromb. Hemost."},{"key":"634_CR133","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1681\/ASN.2016060637","volume":"28","author":"M Mossberg","year":"2017","unstructured":"Mossberg, M. et al. C1-inhibitor decreases the release of vasculitis-like chemotactic endothelial microvesicles. J. Am. Soc. Nephrol. 28, 2472\u20132481 (2017). This study shows that B1R-positive endothelial microvesicles are chemotactic for neutrophils and that this effect could be reduced by C1 inhibitor.","journal-title":"J. Am. Soc. Nephrol."},{"key":"634_CR134","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000063797","volume":"66","author":"I Paegelow","year":"2002","unstructured":"Paegelow, I., Trzeczak, S., B\u00f6ckmann, S. & Vietinghoff, G. Migratory responses of polymorphonuclear leukocytes to kinin peptides. Pharmacology 66, 153\u2013161 (2002).","journal-title":"Pharmacology"},{"key":"634_CR135","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/ATVBAHA.114.304114","volume":"34","author":"TJ Gould","year":"2014","unstructured":"Gould, T. J. et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler. Thromb. Vasc. Biol. 34, 1977\u20131984 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"634_CR136","doi-asserted-by":"crossref","first-page":"222ra217","DOI":"10.1126\/scitranslmed.3006804","volume":"6","author":"M Larsson","year":"2014","unstructured":"Larsson, M. et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci. Transl. Med. 6, 222ra217 (2014).","journal-title":"Sci. Transl. Med."},{"key":"634_CR137","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/scel.1995.0037","volume":"6","author":"PJ Sims","year":"1995","unstructured":"Sims, P. J. & Wiedmer, T. Induction of cellular procoagulant activity by the membrane attack complex of complement. Semin. Cell Biol. 6, 275\u2013282 (1995).","journal-title":"Semin. Cell Biol."},{"key":"634_CR138","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5482\/HAMO-12-12-0025","volume":"33","author":"D Karpman","year":"2013","unstructured":"Karpman, D. & Tati, R. Complement activation in thrombotic microangiopathy. Hamostaseologie 33, 96\u2013104 (2013).","journal-title":"Hamostaseologie"},{"key":"634_CR139","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1084\/jem.182.6.1807","volume":"182","author":"S Saadi","year":"1995","unstructured":"Saadi, S., Holzknecht, R. A., Patte, C. P., Stern, D. M. & Platt, J. L. Complement-mediated regulation of tissue factor activity in endothelium. J. Exp. Med. 182, 1807\u20131814 (1995).","journal-title":"J. Exp. Med."},{"key":"634_CR140","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1016\/S0021-9258(19)39666-8","volume":"265","author":"KK Hamilton","year":"1990","unstructured":"Hamilton, K. K., Hattori, R., Esmon, C. T. & Sims, P. J. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J. Biol. Chem. 265, 3809\u20133814 (1990).","journal-title":"J. Biol. Chem."},{"key":"634_CR141","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","volume":"12","author":"M Huber-Lang","year":"2006","unstructured":"Huber-Lang, M. et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12, 682\u2013687 (2006).","journal-title":"Nat. Med."},{"key":"634_CR142","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","volume":"185","author":"U Amara","year":"2010","unstructured":"Amara, U. et al. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185, 5628\u20135636 (2010).","journal-title":"J. Immunol."},{"key":"634_CR143","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1016\/S0021-9258(18)81901-9","volume":"264","author":"R Hattori","year":"1989","unstructured":"Hattori, R., Hamilton, K. K., McEver, R. P. & Sims, P. J. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J. Biol. Chem. 264, 9053\u20139060 (1989).","journal-title":"J. Biol. Chem."},{"key":"634_CR144","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.4049\/jimmunol.1301221","volume":"191","author":"R Tati","year":"2013","unstructured":"Tati, R. et al. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J. Immunol. 191, 2184\u20132193 (2013).","journal-title":"J. Immunol."},{"key":"634_CR145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1373\/clinchem.2015.251314","volume":"62","author":"I N\u00f8rgaard","year":"2016","unstructured":"N\u00f8rgaard, I., Nielsen, S. F. & Nordestgaard, B. G. Complement C3 and high risk of venous thromboembolism: 80517 individuals from the Copenhagen General Population Study. Clin. Chem. 62, 525\u2013534 (2016).","journal-title":"Clin. Chem."},{"key":"634_CR146","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2006-939769","volume":"32","author":"D Karpman","year":"2006","unstructured":"Karpman, D., Manea, M., Vaziri-Sani, F., St\u00e5hl, A. L. & Kristoffersson, A. C. Platelet activation in hemolytic uremic syndrome. Semin. Thromb. Hemost. 32, 128\u2013145 (2006).","journal-title":"Semin. Thromb. Hemost."},{"key":"634_CR147","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.20041497","volume":"201","author":"I Del Conde","year":"2005","unstructured":"Del Conde, I., Cr\u00faz, M. A., Zhang, H., L\u00f3pez, J. A. & Afshar-Kharghan, V. Platelet activation leads to activation and propagation of the complement system. J. Exp. Med. 201, 871\u2013879 (2005).","journal-title":"J. Exp. Med."},{"key":"634_CR148","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1172\/JCI108261","volume":"57","author":"TS Zimmerman","year":"1976","unstructured":"Zimmerman, T. S. & Kolb, W. P. Human platelet-initiated formation and uptake of the C5-9 complex of human complement. J. Clin. Invest. 57, 203\u2013211 (1976).","journal-title":"J. Clin. Invest."},{"key":"634_CR149","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.150.3.633","volume":"150","author":"MJ Polley","year":"1979","unstructured":"Polley, M. J. & Nachman, R. L. Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex. J. Exp. Med. 150, 633\u2013645 (1979).","journal-title":"J. Exp. Med."},{"key":"634_CR150","volume":"4","author":"AL St\u00e5hl","year":"2009","unstructured":"St\u00e5hl, A. L., Sartz, L., Nelsson, A., B\u00e9k\u00e1ssy, Z. D. & Karpman, D. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS ONE 4, e6990 (2009).","journal-title":"PLoS ONE"},{"key":"634_CR151","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1084\/jem.158.2.603","volume":"158","author":"MJ Polley","year":"1983","unstructured":"Polley, M. J. & Nachman, R. L. Human platelet activation by C3a and C3a des-arg. J. Exp. Med. 158, 603\u2013615 (1983).","journal-title":"J. Exp. Med."},{"key":"634_CR152","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1172\/JCI118195","volume":"96","author":"CS Rinder","year":"1995","unstructured":"Rinder, C. S. et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J. Clin. Invest. 96, 1564\u20131572 (1995).","journal-title":"J. Clin. Invest."},{"key":"634_CR153","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1172\/JCI16651","volume":"111","author":"T Manuelian","year":"2003","unstructured":"Manuelian, T. et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 111, 1181\u20131190 (2003).","journal-title":"J. Clin. Invest."},{"key":"634_CR154","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2007-08-106153","volume":"111","author":"AL St\u00e5hl","year":"2008","unstructured":"St\u00e5hl, A. L. et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111, 5307\u20135315 (2008).","journal-title":"Blood"},{"key":"634_CR155","doi-asserted-by":"crossref","first-page":"619705","DOI":"10.3389\/fimmu.2020.619705","volume":"11","author":"D Michailidou","year":"2020","unstructured":"Michailidou, D., Mustelin, T. & Lood, C. Role of neutrophils in systemic vasculitides. Front. Immunol. 11, 619705 (2020).","journal-title":"Front. Immunol."},{"key":"634_CR156","first-page":"779","volume":"24","author":"GT Bleian","year":"1978","unstructured":"Bleian, G. T., Pogosian, A. S., Stepanian, M. A. & Osipova, E. N. [Role of the blood kinin system in the pathogenesis of the hemorrhagic syndrome in hemorrhagic vasculitis]. Vopr. Med. Khim 24, 779\u2013781 (1978).","journal-title":"Vopr. Med. Khim"},{"key":"634_CR157","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-88-6-764","volume":"88","author":"T Yamada","year":"1978","unstructured":"Yamada, T., Harber, P., Pettit, G. W., Wing, D. A. & Oster, C. N. Activation of the kallikrein-kinin system in Rocky Mountain spotted fever. Ann. Intern. Med. 88, 764\u2013768 (1978).","journal-title":"Ann. Intern. Med."},{"key":"634_CR158","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(02)09743-X","volume":"360","author":"R Kahn","year":"2002","unstructured":"Kahn, R. et al. Contact-system activation in children with vasculitis. Lancet 360, 535\u2013541 (2002).","journal-title":"Lancet"},{"key":"634_CR159","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1681\/ASN.2009090887","volume":"21","author":"J Klein","year":"2010","unstructured":"Klein, J. et al. Blockade of the kinin B1 receptor ameloriates glomerulonephritis. J. Am. Soc. Nephrol. 21, 1157\u20131164 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"634_CR160","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1681\/ASN.2019010032","volume":"31","author":"P Hu","year":"2020","unstructured":"Hu, P. et al. Kinin B1 receptor is important in the pathogenesis of myeloperoxidase-specific ANCA GN. J. Am. Soc. Nephrol. 31, 297\u2013307 (2020). This study demonstrates the role of B1R for inflammation in ANCA-associated glomerulonephritis.","journal-title":"J. Am. Soc. Nephrol."},{"key":"634_CR161","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.kint.2016.09.023","volume":"91","author":"R Kahn","year":"2017","unstructured":"Kahn, R. et al. Microvesicle transfer of kinin B1-receptors is a novel inflammatory mechanism in vasculitis. Kidney Int. 91, 96\u2013105 (2017). This work shows that circulating leukocyte-derived microvesicles can transfer B1R to cells and thereby promote kinin-mediated inflammation.","journal-title":"Kidney Int."},{"key":"634_CR162","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","volume":"13","author":"M Chen","year":"2017","unstructured":"Chen, M., Jayne, D. R. W. & Zhao, M. H. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat. Rev. Nephrol. 13, 359\u2013367 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"634_CR163","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ebiom.2019.08.020","volume":"47","author":"I Lopatko Fagerstr\u00f6m","year":"2019","unstructured":"Lopatko Fagerstr\u00f6m, I. et al. Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation. EBioMedicine 47, 319\u2013328 (2019). This study shows that blockade of kinin receptors blocked endothelial complement deposition in vitro and in vivo.","journal-title":"EBioMedicine"},{"key":"634_CR164","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/art.39239","volume":"67","author":"YM Huang","year":"2015","unstructured":"Huang, Y. M., Wang, H., Wang, C., Chen, M. & Zhao, M. H. Promotion of hypercoagulability in antineutrophil cytoplasmic antibody-associated vasculitis by C5a-induced tissue factor-expressing microparticles and neutrophil extracellular traps. Arthritis Rheumatol. 67, 2780\u20132790 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"634_CR165","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne, D. R. W., Merkel, P. A., Schall, T. J. & Bekker, P. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384, 599\u2013609 (2021).","journal-title":"N. Engl. J. Med."},{"key":"634_CR166","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.kint.2020.05.013","volume":"98","author":"M Noris","year":"2020","unstructured":"Noris, M., Benigni, A. & Remuzzi, G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 98, 314\u2013322 (2020).","journal-title":"Kidney Int."},{"key":"634_CR167","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417\u20131418 (2020).","journal-title":"Lancet"},{"key":"634_CR168","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448 (2020).","journal-title":"Science"},{"key":"634_CR169","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cca.2020.04.027","volume":"507","author":"BM Henry","year":"2020","unstructured":"Henry, B. M., Vikse, J., Benoit, S., Favaloro, E. J. & Lippi, G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin. Chim. Acta 507, 167\u2013173 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"634_CR170","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","volume":"277","author":"C Vickers","year":"2002","unstructured":"Vickers, C. et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838\u201314843 (2002). This article comprehensively lists ACE2 substrates.","journal-title":"J. Biol. Chem."},{"key":"634_CR171","doi-asserted-by":"crossref","first-page":"L17","DOI":"10.1152\/ajplung.00498.2016","volume":"314","author":"CP Sodhi","year":"2018","unstructured":"Sodhi, C. P. et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin\/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am. J. Physiol. Lung Cell Mol. Physiol. 314, L17\u2013L31 (2018).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"634_CR172","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(20)30418-5","volume":"8","author":"A Zoufaly","year":"2020","unstructured":"Zoufaly, A. et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. 8, 1154\u20131158 (2020).","journal-title":"Lancet Respir. Med."},{"key":"634_CR173","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 63, 364\u2013374 (2020).","journal-title":"Sci. China Life Sci."},{"key":"634_CR174","volume":"24","author":"Z Wu","year":"2020","unstructured":"Wu, Z. et al. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Crit. Care 24, 290 (2020).","journal-title":"Crit. Care"},{"key":"634_CR175","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ajh\/hpaa169","volume":"34","author":"M Rieder","year":"2020","unstructured":"Rieder, M. et al. Serum ACE-2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19. Am. J. Hypertens 34, 278\u2013281 (2020).","journal-title":"Am. J. Hypertens"},{"key":"634_CR176","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.59177","volume":"9","author":"MR Garvin","year":"2020","unstructured":"Garvin, M. R. et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife 9, e591747 (2020).","journal-title":"eLife"},{"key":"634_CR177","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.mayocp.2020.04.028","volume":"95","author":"JM Bos","year":"2020","unstructured":"Bos, J. M. et al. Marked up-regulation of ACE2 in hearts of patients with obstructive hypertrophic cardiomyopathy: implications for SARS-CoV-2-mediated COVID-19. Mayo Clin. Proc. 95, 1354\u20131368 (2020).","journal-title":"Mayo Clin. Proc."},{"key":"634_CR178","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.drudis.2021.04.006","volume":"26","author":"AQ Dean","year":"2021","unstructured":"Dean, A. Q. et al. The fight against COVID-19: striking a balance in the renin-angiotensin system. Drug Discov. Today 26, 2214\u20132220 (2021).","journal-title":"Drug Discov. Today"},{"key":"634_CR179","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1164\/rccm.202101-0142LE","volume":"203","author":"R Reindl-Schwaighofer","year":"2021","unstructured":"Reindl-Schwaighofer, R. et al. ACE2 elevation in severe COVID-19. Am. J. Respir. Crit. Care Med. 203, 1191\u20131196 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"634_CR180","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.3389\/fimmu.2020.02014","volume":"11","author":"S Meini","year":"2020","unstructured":"Meini, S. et al. Understanding the pathophysiology of COVID-19: could the contact system be the key? Front. Immunol. 11, 2014 (2020).","journal-title":"Front. Immunol."},{"key":"634_CR181","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57555","volume":"9","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk, F. L. et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife 9, e57555 (2020).","journal-title":"eLife"},{"key":"634_CR182","doi-asserted-by":"crossref","first-page":"627579","DOI":"10.3389\/fimmu.2021.627579","volume":"12","author":"M Lipcsey","year":"2021","unstructured":"Lipcsey, M. et al. The outcome of critically ill COVID-19 patients is linked to thromboinflammation dominated by the kallikrein\/kinin system. Front. Immunol. 12, 627579 (2021).","journal-title":"Front. Immunol."},{"key":"634_CR183","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jaci.2020.10.025","volume":"147","author":"AP Kaplan","year":"2021","unstructured":"Kaplan, A. P. & Ghebrehiwet, B. Pathways for bradykinin formation and interrelationship with complement as a cause of edematous lung in COVID-19 patients. J. Allergy Clin. Immunol. 147, 507\u2013509 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"634_CR184","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.16938","volume":"190","author":"TM Thomson","year":"2020","unstructured":"Thomson, T. M., Toscano-Guerra, E., Casis, E. & Paciucci, R. C1 esterase inhibitor and the contact system in COVID-19. Br. J. Haematol. 190, 520\u2013524 (2020).","journal-title":"Br. J. Haematol."},{"key":"634_CR185","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1161\/ATVBAHA.120.315175","volume":"40","author":"F Taus","year":"2020","unstructured":"Taus, F. et al. Platelets promote thromboinflammation in SARS-CoV-2 pneumonia. Arterioscler. Thromb. Vasc. Biol. 40, 2975\u20132989 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"634_CR186","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","volume":"383","author":"GI Rice","year":"2004","unstructured":"Rice, G. I., Thomas, D. A., Grant, P. J., Turner, A. J. & Hooper, N. M. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem. J. 383, 45\u201351 (2004).","journal-title":"Biochem. J."},{"key":"634_CR187","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan, M. et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N. Engl. J. Med. 382, 1653\u20131659 (2020).","journal-title":"N. Engl. J. Med."},{"key":"634_CR188","doi-asserted-by":"crossref","first-page":"102907","DOI":"10.1016\/j.ebiom.2020.102907","volume":"58","author":"MK Chung","year":"2020","unstructured":"Chung, M. K. et al. SARS-CoV-2 and ACE2: the biology and clinical data settling the ARB and ACEI controversy. EBioMedicine 58, 102907 (2020).","journal-title":"EBioMedicine"},{"key":"634_CR189","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1161\/HYPERTENSIONAHA.120.15989","volume":"76","author":"CK Chan","year":"2020","unstructured":"Chan, C. K. et al. Renin-angiotensin-aldosterone system inhibitors and risks of severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis. Hypertension 76, 1563\u20131571 (2020).","journal-title":"Hypertension"},{"key":"634_CR190","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ajh\/hpaa168","volume":"34","author":"S Dublin","year":"2020","unstructured":"Dublin, S. et al. Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study. Am. J. Hypertens. 34, 339\u2013347 (2020).","journal-title":"Am. J. Hypertens."},{"key":"634_CR191","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40264-020-00994-5","volume":"43","author":"G Trifir\u00f2","year":"2020","unstructured":"Trifir\u00f2, G. et al. Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort study of 43,000 patients. Drug. Saf. 43, 1297\u20131308 (2020).","journal-title":"Drug. Saf."},{"key":"634_CR192","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.120.16314","volume":"77","author":"L Semenzato","year":"2021","unstructured":"Semenzato, L. et al. Antihypertensive drugs and COVID-19 risk: a cohort study of 2 million hypertensive patients. Hypertension 77, 833\u2013842 (2021).","journal-title":"Hypertension"},{"key":"634_CR193","volume":"4","author":"R Wang","year":"2015","unstructured":"Wang, R., Xiao, H., Guo, R., Li, Y. & Shen, B. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg. Microbes Infect. 4, e28 (2015).","journal-title":"Emerg. Microbes Infect."},{"key":"634_CR194","doi-asserted-by":"crossref","first-page":"25018","DOI":"10.1073\/pnas.2010540117","volume":"117","author":"JC Holter","year":"2020","unstructured":"Holter, J. C. et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc. Natl Acad. Sci. USA 117, 25018\u201325025 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR195","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.29.20041962","author":"T Gao","year":"2020","unstructured":"Gao, T. et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv https:\/\/doi.org\/10.1101\/2020.03.29.20041962 (2020).","journal-title":"medRxiv"},{"key":"634_CR196","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood.2020008248","volume":"136","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 136, 2080\u20132089 (2020).","journal-title":"Blood"},{"key":"634_CR197","volume":"6","author":"B Yan","year":"2021","unstructured":"Yan, B. et al. SARS-CoV-2 drives JAK1\/2-dependent local complement hyperactivation. Sci. Immunol. 6, eabg0833 (2021).","journal-title":"Sci. Immunol."},{"key":"634_CR198","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2020.05.032","volume":"182","author":"B Shen","year":"2020","unstructured":"Shen, B. et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 182, 59\u201372.e15 (2020).","journal-title":"Cell"},{"key":"634_CR199","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaci.2020.05.006","volume":"146","author":"M Cugno","year":"2020","unstructured":"Cugno, M. et al. Complement activation in patients with COVID-19: a novel therapeutic target. J. Allergy Clin. Immunol. 146, 215\u2013217 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"634_CR200","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3389\/fimmu.2020.02072","volume":"11","author":"P Urwyler","year":"2020","unstructured":"Urwyler, P. et al. Treatment of COVID-19 with conestat alfa, a regulator of the complement, contact activation and kallikrein-kinin system. Front. Immunol. 11, 2072 (2020).","journal-title":"Front. Immunol."},{"key":"634_CR201","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3324\/haematol.2020.260117","volume":"105","author":"L Regis Peffault de","year":"2020","unstructured":"Regis Peffault de, L. et al. Complement C5 inhibition in patients with COVID-19 \u2014 a promising target? Haematologica 105, 2847\u20132850 (2020).","journal-title":"Haematologica"},{"key":"634_CR202","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1182\/bloodadvances.2020003471","volume":"4","author":"C Diorio","year":"2020","unstructured":"Diorio, C. et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 4, 6051\u20136063 (2020).","journal-title":"Blood Adv."},{"key":"634_CR203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/infdis\/jiaa646","volume":"223","author":"AH de Nooijer","year":"2021","unstructured":"de Nooijer, A. H. et al. Complement activation in the disease course of coronavirus disease 2019 and its effects on clinical outcomes. J. Infect. Dis. 223, 214\u2013224 (2021).","journal-title":"J. Infect. Dis."},{"key":"634_CR204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","volume":"220","author":"C Magro","year":"2020","unstructured":"Magro, C. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl. Res. 220, 1\u201313 (2020).","journal-title":"Transl. Res."},{"key":"634_CR205","doi-asserted-by":"crossref","first-page":"594849","DOI":"10.3389\/fimmu.2020.594849","volume":"11","author":"F Pfister","year":"2020","unstructured":"Pfister, F. et al. Complement activation in kidneys of patients with COVID-19. Front. Immunol. 11, 594849 (2020).","journal-title":"Front. Immunol."},{"key":"634_CR206","doi-asserted-by":"crossref","first-page":"152001","DOI":"10.1016\/j.imbio.2020.152001","volume":"225","author":"A Rambaldi","year":"2020","unstructured":"Rambaldi, A. et al. Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology 225, 152001 (2020).","journal-title":"Immunobiology"},{"key":"634_CR207","doi-asserted-by":"crossref","first-page":"100590","DOI":"10.1016\/j.eclinm.2020.100590","volume":"28","author":"D Annane","year":"2020","unstructured":"Annane, D. et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine 28, 100590 (2020).","journal-title":"EClinicalMedicine"},{"key":"634_CR208","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40620-020-00858-2","volume":"33","author":"R Mahajan","year":"2020","unstructured":"Mahajan, R., Lipton, M., Broglie, L., Jain, N. G. & Uy, N. S. Eculizumab treatment for renal failure in a pediatric patient with COVID-19. J. Nephrol. 33, 1373\u20131376 (2020).","journal-title":"J. Nephrol."},{"key":"634_CR209","doi-asserted-by":"crossref","first-page":"108598","DOI":"10.1016\/j.clim.2020.108598","volume":"220","author":"DC Mastellos","year":"2020","unstructured":"Mastellos, D. C. et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin. Immunol. 220, 108598 (2020).","journal-title":"Clin. Immunol."},{"key":"634_CR210","first-page":"4040","volume":"24","author":"F Diurno","year":"2020","unstructured":"Diurno, F. et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur. Rev. Med. Pharmacol. Sci. 24, 4040\u20134047 (2020).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"634_CR211","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1016\/S2665-9913(20)30341-6","volume":"2","author":"APJ Vlaar","year":"2020","unstructured":"Vlaar, A. P. J. et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2, e764\u2013e773 (2020).","journal-title":"Lancet Rheumatol."},{"key":"634_CR212","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17708","volume":"3","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk, F. L. et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw. Open 3, e2017708 (2020).","journal-title":"JAMA Netw. Open"},{"key":"634_CR213","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/v13020309","volume":"13","author":"E Mansour","year":"2021","unstructured":"Mansour, E. et al. Safety and outcomes associated with the pharmacological inhibition of the kinin-kallikrein system in severe COVID-19. Viruses 13, 309 (2021).","journal-title":"Viruses"},{"key":"634_CR214","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1161\/01.CIR.0000148824.93600.F3","volume":"110","author":"YN Nabah","year":"2004","unstructured":"Nabah, Y. N. et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 110, 3581\u20133586 (2004).","journal-title":"Circulation"},{"key":"634_CR215","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/HYPERTENSIONAHA.110.158220","volume":"56","author":"EY Senchenkova","year":"2010","unstructured":"Senchenkova, E. Y., Russell, J., Almeida-Paula, L. D., Harding, J. W. & Granger, D. N. Angiotensin II-mediated microvascular thrombosis. Hypertension 56, 1089\u20131095 (2010).","journal-title":"Hypertension"},{"key":"634_CR216","doi-asserted-by":"crossref","first-page":"3s","DOI":"10.1016\/S0895-7061(01)02273-7","volume":"15","author":"DE Vaughan","year":"2002","unstructured":"Vaughan, D. E. Angiotensin and vascular fibrinolytic balance. Am. J. Hypertens. 15, 3s\u20138s (2002).","journal-title":"Am. J. Hypertens."},{"key":"634_CR217","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.peptides.2013.04.014","volume":"46","author":"VG Yugandhar","year":"2013","unstructured":"Yugandhar, V. G. & Clark, M. A. Angiotensin III: a physiological relevant peptide of the renin angiotensin system. Peptides 46, 26\u201332 (2013).","journal-title":"Peptides"},{"key":"634_CR218","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.tcm.2006.10.003","volume":"17","author":"M Ruiz-Ortega","year":"2007","unstructured":"Ruiz-Ortega, M., Esteban, V. & Egido, J. The regulation of the inflammatory response through nuclear factor- \u03bab pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovasc. Med. 17, 19\u201325 (2007).","journal-title":"Trends Cardiovasc. Med."},{"key":"634_CR219","doi-asserted-by":"crossref","first-page":"147032031879958","DOI":"10.1177\/1470320318799587","volume":"19","author":"QG Wang","year":"2018","unstructured":"Wang, Q. G. et al. Angiotensin IV suppresses inflammation in the brains of rats with chronic cerebral hypoperfusion. J. Renin Angiotensin Aldosterone Syst. 19, 1470320318799587 (2018).","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"634_CR220","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1042\/CS20130449","volume":"127","author":"MP Ocaranza","year":"2014","unstructured":"Ocaranza, M. P. et al. Recent insights and therapeutic perspectives of angiotensin-(1\u20139) in the cardiovascular system. Clin. Sci. 127, 549\u2013557 (2014).","journal-title":"Clin. Sci."},{"key":"634_CR221","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/01.ATV.0000253889.09765.5f","volume":"27","author":"V Jankowski","year":"2007","unstructured":"Jankowski, V. et al. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler. Thromb. Vasc. Biol. 27, 297\u2013302 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"634_CR222","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","volume":"112","author":"RQ Lautner","year":"2013","unstructured":"Lautner, R. Q. et al. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ. Res. 112, 1104\u20131111 (2013).","journal-title":"Circ. Res."},{"key":"634_CR223","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4049\/jimmunol.134.2.1115","volume":"134","author":"J Bj\u00f6rk","year":"1985","unstructured":"Bj\u00f6rk, J., Hugli, T. E. & Smedeg\u00e5rd, G. Microvascular effects of anaphylatoxins C3a and C5a. J. Immunol. 134, 1115\u20131119 (1985).","journal-title":"J. Immunol."},{"key":"634_CR224","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","volume":"46","author":"A Klos","year":"2009","unstructured":"Klos, A. et al. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46, 2753\u20132766 (2009).","journal-title":"Mol. Immunol."},{"key":"634_CR225","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140966","volume":"131","author":"NE Propson","year":"2021","unstructured":"Propson, N. E., Roy, E. R., Litvinchuk, A., K\u00f6hl, J. & Zheng, H. Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J. Clin. Invest. 131, e140966 (2021).","journal-title":"J. Clin. Invest."},{"key":"634_CR226","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1161\/CIRCULATIONAHA.118.034600","volume":"138","author":"RJ Sauter","year":"2018","unstructured":"Sauter, R. J. et al. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis. Circulation 138, 1720\u20131735 (2018).","journal-title":"Circulation"},{"key":"634_CR227","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.1073\/pnas.1707364114","volume":"114","author":"H Wang","year":"2017","unstructured":"Wang, H., Ricklin, D. & Lambris, J. D. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proc. Natl Acad. Sci. USA 114, 10948\u201310953 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR228","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.imbio.2015.04.006","volume":"221","author":"BP Morgan","year":"2016","unstructured":"Morgan, B. P. The membrane attack complex as an inflammatory trigger. Immunobiology 221, 747\u2013751 (2016).","journal-title":"Immunobiology"},{"key":"634_CR229","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2011.06.006","volume":"140","author":"F Bossi","year":"2011","unstructured":"Bossi, F., Peerschke, E. I., Ghebrehiwet, B. & Tedesco, F. Cross-talk between the complement and the kinin system in vascular permeability. Immunol. Lett. 140, 7\u201313 (2011).","journal-title":"Immunol. Lett."},{"key":"634_CR230","first-page":"357","volume":"50","author":"F Marceau","year":"1998","unstructured":"Marceau, F., Hess, J. F. & Bachvarov, D. R. The B1 receptors for kinins. Pharmacol. Rev. 50, 357\u2013386 (1998).","journal-title":"Pharmacol. Rev."},{"key":"634_CR231","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2012.249","volume":"93","author":"JM Balaguer","year":"2013","unstructured":"Balaguer, J. M. et al. Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial. Clin. Pharmacol. Ther. 93, 326\u2013334 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"634_CR232","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1189\/jlb.1205744","volume":"80","author":"P Ehrenfeld","year":"2006","unstructured":"Ehrenfeld, P. et al. Activation of kinin B1 receptors induces chemotaxis of human neutrophils. J. Leukoc. Biol. 80, 117\u2013124 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"634_CR233","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1189\/jlb.0109012","volume":"86","author":"P Ehrenfeld","year":"2009","unstructured":"Ehrenfeld, P. et al. Kinin B1 receptor activation turns on exocytosis of matrix metalloprotease-9 and myeloperoxidase in human neutrophils: involvement of mitogen-activated protein kinase family. J. Leukoc. Biol. 86, 1179\u20131189 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"634_CR234","doi-asserted-by":"crossref","first-page":"105096","DOI":"10.1016\/j.phrs.2020.105096","volume":"160","author":"C Fang","year":"2020","unstructured":"Fang, C. & Schmaier, A. H. Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein\/kinin and the renin-angiotensin systems. Pharmacol. Res. 160, 105096 (2020).","journal-title":"Pharmacol. Res."},{"key":"634_CR235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1721727X15577736","volume":"13","author":"N Tidjane","year":"2015","unstructured":"Tidjane, N. et al. A primary role for kinin B1 receptor in inflammation, organ damage, and lethal thrombosis in a rat model of septic shock in diabetes. Eur. J. Inflamm. 13, 40\u201352 (2015).","journal-title":"Eur. J. Inflamm."},{"key":"634_CR236","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/01.ATV.0000157157.78822.25","volume":"25","author":"NL Cruden","year":"2005","unstructured":"Cruden, N. L. et al. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure. Arterioscler. Thromb. Vasc. Biol. 25, 772\u2013777 (2005).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"634_CR237","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/207871a0","volume":"207","author":"E Werle","year":"1965","unstructured":"Werle, E. & Schievelbein, H. Activity of nicotine and inactivity of kallikrein and kallidin in aggregation of blood platelets. Nature 207, 871\u2013872 (1965).","journal-title":"Nature"},{"key":"634_CR238","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/21505594.2019.1640035","volume":"10","author":"M Muenstermann","year":"2019","unstructured":"Muenstermann, M. et al. Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections. Virulence 10, 677\u2013694 (2019).","journal-title":"Virulence"},{"key":"634_CR239","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000371423","volume":"7","author":"SR Barnum","year":"2015","unstructured":"Barnum, S. R. C4a: an anaphylatoxin in name only. J. Innate Immun. 7, 333\u2013339 (2015).","journal-title":"J. Innate Immun."},{"key":"634_CR240","doi-asserted-by":"crossref","first-page":"H644","DOI":"10.1152\/ajpheart.00210.2013","volume":"305","author":"N Moniwa","year":"2013","unstructured":"Moniwa, N. et al. Primacy of angiotensin converting enzyme in angiotensin-(1\u201312) metabolism. Am. J. Physiol. Heart Circ. Physiol. 305, H644\u2013H650 (2013).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"634_CR241","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0006-291X(85)80180-7","volume":"127","author":"CF Reilly","year":"1985","unstructured":"Reilly, C. F., Schechter, N. B. & Travis, J. Inactivation of bradykinin and kallidin by cathepsin G and mast cell chymase. Biochem. Biophys. Res. Commun. 127, 443\u2013449 (1985).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"634_CR242","volume":"6","author":"S Ahmad","year":"2011","unstructured":"Ahmad, S. et al. Chymase-dependent generation of angiotensin II from angiotensin-(1\u201312) in human atrial tissue. PLoS ONE 6, e28501 (2011).","journal-title":"PLoS ONE"},{"key":"634_CR243","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/HYPERTENSIONAHA.109.128819","volume":"53","author":"JC Velez","year":"2009","unstructured":"Velez, J. C. et al. Angiotensin I is largely converted to angiotensin (1\u20137) and angiotensin (2\u201310) by isolated rat glomeruli. Hypertension 53, 790\u2013797 (2009).","journal-title":"Hypertension"},{"key":"634_CR244","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1161\/01.CIR.99.15.1984","volume":"99","author":"JO Kokkonen","year":"1999","unstructured":"Kokkonen, J. O., Kuoppala, A., Saarinen, J., Lindstedt, K. A. & Kovanen, P. T. Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation 99, 1984\u20131990 (1999).","journal-title":"Circulation"},{"key":"634_CR245","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/jpet.105.083063","volume":"313","author":"FG Pelorosso","year":"2005","unstructured":"Pelorosso, F. G., Brodsky, P. T., Zold, C. L. & Rothlin, R. P. Potentiation of des-Arg9-kallidin-induced vasoconstrictor responses by metallopeptidase inhibition in isolated human umbilical artery. J. Pharmacol. Exp. Ther. 313, 1355\u20131360 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"634_CR246","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/jpet.108.136911","volume":"326","author":"C Sand\u00e9n","year":"2008","unstructured":"Sand\u00e9n, C., Enquist, J., Bengtson, S. H., Herwald, H. & Leeb-Lundberg, L. M. Kinin B2 receptor-mediated bradykinin internalization and metalloendopeptidase EP24.15-dependent intracellular bradykinin degradation. J. Pharmacol. Exp. Ther. 326, 24\u201332 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"634_CR247","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1016\/S0021-9258(17)34557-X","volume":"253","author":"CE Odya","year":"1978","unstructured":"Odya, C. E., Marinkovic, D. V., Hammon, K. J., Stewart, T. A. & Erd\u00f6s, E. G. Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J. Biol. Chem. 253, 5927\u20135931 (1978).","journal-title":"J. Biol. Chem."},{"key":"634_CR248","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbrc.2010.12.036","volume":"405","author":"SM Chajkowski","year":"2011","unstructured":"Chajkowski, S. M. et al. Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase. Biochem. Biophys. Res. Commun. 405, 338\u2013343 (2011).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"634_CR249","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/oxfordjournals.jbchem.a122126","volume":"102","author":"M Ideishi","year":"1987","unstructured":"Ideishi, M., Ikeda, M. & Arakawa, K. Direct angiotensin II formation by rat submandibular gland kallikrein. J. Biochem. 102, 859\u2013868 (1987).","journal-title":"J. Biochem."},{"key":"634_CR250","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00004872-199715060-00014","volume":"15","author":"M Sasaguri","year":"1997","unstructured":"Sasaguri, M. et al. Purification and characterization of a kinin- and angiotensin II-forming enzyme in the dog heart. J. Hypertens. 15, 675\u2013682 (1997).","journal-title":"J. Hypertens."},{"key":"634_CR251","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.4049\/jimmunol.1202999","volume":"191","author":"K Oikonomopoulou","year":"2013","unstructured":"Oikonomopoulou, K. et al. Induction of complement C3a receptor responses by kallikrein-related peptidase 14. J. Immunol. 191, 3858\u20133866 (2013).","journal-title":"J. Immunol."},{"key":"634_CR252","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000484257","volume":"10","author":"S Irmscher","year":"2018","unstructured":"Irmscher, S. et al. Kallikrein cleaves C3 and activates complement. J. Innate Immun. 10, 94\u2013105 (2018).","journal-title":"J. Innate Immun."},{"key":"634_CR253","first-page":"587","volume":"45","author":"RG DiScipio","year":"1982","unstructured":"DiScipio, R. G. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 45, 587\u2013595 (1982).","journal-title":"Immunology"},{"key":"634_CR254","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1172\/JCI110898","volume":"71","author":"B Ghebrehiwet","year":"1983","unstructured":"Ghebrehiwet, B., Randazzo, B. P., Dunn, J. T., Silverberg, M. & Kaplan, A. P. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J. Clin. Invest. 71, 1450\u20131456 (1983).","journal-title":"J. Clin. Invest."},{"key":"634_CR255","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/S0021-9258(18)94167-0","volume":"264","author":"RA Skidgel","year":"1989","unstructured":"Skidgel, R. A., Davis, R. M. & Tan, F. Human carboxypeptidase M. Purification and characterization of a membrane-bound carboxypeptidase that cleaves peptide hormones. J. Biol. Chem. 264, 2236\u20132241 (1989).","journal-title":"J. Biol. Chem."},{"key":"634_CR256","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1172\/JCI106462","volume":"49","author":"VA Bokisch","year":"1970","unstructured":"Bokisch, V. A. & M\u00fcller-Eberhard, H. J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 49, 2427\u20132436 (1970).","journal-title":"J. Clin. Invest."},{"key":"634_CR257","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1348-0421.2002.tb02669.x","volume":"46","author":"WD Campbell","year":"2002","unstructured":"Campbell, W. D., Lazoura, E., Okada, N. & Okada, H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol. Immunol. 46, 131\u2013134 (2002).","journal-title":"Microbiol. Immunol."},{"key":"634_CR258","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/jth.13261","volume":"14","author":"T Plug","year":"2016","unstructured":"Plug, T. & Meijers, J. C. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor. J. Thromb. Haemost. 14, 633\u2013644 (2016).","journal-title":"J. Thromb. Haemost."},{"key":"634_CR259","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11906-008-0022-1","volume":"10","author":"M Krop","year":"2008","unstructured":"Krop, M. & Danser, A. H. Circulating versus tissue renin-angiotensin system: on the origin of (pro)renin. Curr. Hypertens. Rep. 10, 112\u2013118 (2008).","journal-title":"Curr. Hypertens. Rep."},{"key":"634_CR260","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ajh.2011.246","volume":"25","author":"A Kurtz","year":"2012","unstructured":"Kurtz, A. Control of renin synthesis and secretion. Am. J. Hypertens. 25, 839\u2013847 (2012).","journal-title":"Am. J. Hypertens."},{"key":"634_CR261","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41581-019-0160-5","volume":"15","author":"A Ichihara","year":"2019","unstructured":"Ichihara, A. & Yatabe, M. S. The (pro)renin receptor in health and disease. Nat. Rev. Nephrol. 15, 693\u2013712 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"634_CR262","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11906-014-0429-9","volume":"16","author":"S Ahmad","year":"2014","unstructured":"Ahmad, S. et al. Angiotensin-(1\u201312): a chymase-mediated cellular angiotensin II substrate. Curr. Hypertens. Rep. 16, 429 (2014).","journal-title":"Curr. Hypertens. Rep."},{"key":"634_CR263","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.peptides.2016.03.017","volume":"79","author":"BM Park","year":"2016","unstructured":"Park, B. M., Cha, S. A., Lee, S. H. & Kim, S. H. Angiotensin IV protects cardiac reperfusion injury by inhibiting apoptosis and inflammation via AT4R in rats. Peptides 79, 66\u201374 (2016).","journal-title":"Peptides"},{"key":"634_CR264","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-0115(98)00039-1","volume":"74","author":"EA Kram\u00e1r","year":"1998","unstructured":"Kram\u00e1r, E. A., Krishnan, R., Harding, J. W. & Wright, J. W. Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. Regul. Pept. 74, 185\u2013192 (1998).","journal-title":"Regul. Pept."},{"key":"634_CR265","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/HYPERTENSIONAHA.116.07572","volume":"68","author":"A Tetzner","year":"2016","unstructured":"Tetzner, A. et al. G-protein-coupled receptor MrgD is a receptor for angiotensin-(1\u20137) involving adenylyl cyclase, cAMP, and phosphokinase A. Hypertension 68, 185\u2013194 (2016).","journal-title":"Hypertension"},{"key":"634_CR266","first-page":"415","volume":"52","author":"M de Gasparo","year":"2000","unstructured":"de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W. & Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415\u2013472 (2000).","journal-title":"Pharmacol. Rev."},{"key":"634_CR267","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1084\/jem.147.3.719","volume":"147","author":"SD Revak","year":"1978","unstructured":"Revak, S. D., Cochrane, C. G., Bouma, B. N. & Griffin, J. H. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J. Exp. Med. 147, 719\u2013729 (1978).","journal-title":"J. Exp. Med."},{"key":"634_CR268","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/pr.57.1.2","volume":"57","author":"LM Leeb-Lundberg","year":"2005","unstructured":"Leeb-Lundberg, L. M., Marceau, F., M\u00fcller-Esterl, W., Pettibone, D. J. & Zuraw, B. L. International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57, 27\u201377 (2005). This is a comprehensive review of kinin receptors.","journal-title":"Pharmacol. Rev."},{"key":"634_CR269","doi-asserted-by":"crossref","first-page":"F795","DOI":"10.1152\/ajprenal.0020.2001","volume":"281","author":"IV Yosipiv","year":"2001","unstructured":"Yosipiv, I. V., Dipp, S. & El-Dahr, S. S. Targeted disruption of the bradykinin B2 receptor gene in mice alters the ontogeny of the renin-angiotensin system. Am. J. Physiol. Ren. Physiol. 281, F795\u2013F801 (2001).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"634_CR270","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/01.HYP.0000228997.88162.a8","volume":"48","author":"PM Abadir","year":"2006","unstructured":"Abadir, P. M., Periasamy, A., Carey, R. M. & Siragy, H. M. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 48, 316\u2013322 (2006).","journal-title":"Hypertension"},{"key":"634_CR271","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/01.HYP.0000090323.58122.5C","volume":"42","author":"PM Abadir","year":"2003","unstructured":"Abadir, P. M., Carey, R. M. & Siragy, H. M. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 42, 600\u2013604 (2003).","journal-title":"Hypertension"},{"key":"634_CR272","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/HYPERTENSIONAHA.116.07874","volume":"68","author":"BD Cerrato","year":"2016","unstructured":"Cerrato, B. D., Carretero, O. A., Janic, B., Grecco, H. E. & Gironacci, M. M. Heteromerization between the bradykinin B2 receptor and the angiotensin-(1\u20137) mas receptor: functional consequences. Hypertension 68, 1039\u20131048 (2016).","journal-title":"Hypertension"},{"key":"634_CR273","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/35024095","volume":"407","author":"S AbdAlla","year":"2000","unstructured":"AbdAlla, S., Lother, H. & Quitterer, U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407, 94\u201398 (2000).","journal-title":"Nature"},{"key":"634_CR274","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14728222.2018.1409724","volume":"22","author":"F Qadri","year":"2018","unstructured":"Qadri, F. & Bader, M. Kinin B1 receptors as a therapeutic target for inflammation. Expert Opin. Ther. Targets 22, 31\u201344 (2018).","journal-title":"Expert Opin. Ther. Targets"},{"key":"634_CR275","doi-asserted-by":"crossref","first-page":"21583","DOI":"10.1016\/S0021-9258(17)31844-6","volume":"269","author":"JG Menke","year":"1994","unstructured":"Menke, J. G. et al. Expression cloning of a human B1 bradykinin receptor. J. Biol. Chem. 269, 21583\u201321586 (1994).","journal-title":"J. Biol. Chem."},{"key":"634_CR276","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1515\/BC.2005.061","volume":"386","author":"VF Merino","year":"2005","unstructured":"Merino, V. F. et al. Molecular structure and transcriptional regulation by nuclear factor- \u03baB of the mouse kinin B1 receptor gene. Biol. Chem. 386, 515\u2013522 (2005).","journal-title":"Biol. Chem."},{"key":"634_CR277","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.4049\/jimmunol.179.7.4849","volume":"179","author":"J Duchene","year":"2007","unstructured":"Duchene, J. et al. A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5. J. Immunol. 179, 4849\u20134856 (2007).","journal-title":"J. Immunol."},{"issue":"Suppl 9","key":"634_CR278","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/00005344-199200209-00015","volume":"20","author":"W Linz","year":"1992","unstructured":"Linz, W. & Sch\u00f6lkens, B. A. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 20 (Suppl 9), S83\u2013S90 (1992).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"634_CR279","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/hc0502.102965","volume":"105","author":"ME Marin-Casta\u00f1o","year":"2002","unstructured":"Marin-Casta\u00f1o, M. E. et al. Induction of functional bradykinin B1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 105, 627\u2013632 (2002).","journal-title":"Circulation"},{"key":"634_CR280","first-page":"605","volume":"294","author":"BM Marcic","year":"2000","unstructured":"Marcic, B. M. & Erd\u00f6s, E. G. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J. Pharmacol. Exp. Ther. 294, 605\u2013612 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"634_CR281","doi-asserted-by":"crossref","first-page":"106081","DOI":"10.1016\/j.intimp.2019.106081","volume":"78","author":"V Montinaro","year":"2020","unstructured":"Montinaro, V. & Cicardi, M. ACE inhibitor-mediated angioedema. Int. Immunopharmacol. 78, 106081 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"634_CR282","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fmed.2018.00257","volume":"5","author":"DJ Campbell","year":"2018","unstructured":"Campbell, D. J. Neprilysin inhibitors and bradykinin. Front. Med. 5, 257 (2018).","journal-title":"Front. Med."},{"key":"634_CR283","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","volume":"68","author":"G Remuzzi","year":"2005","unstructured":"Remuzzi, G., Perico, N., Macia, M. & Ruggenenti, P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. Suppl. 68, S57\u2013S65 (2005).","journal-title":"Kidney Int. Suppl."},{"key":"634_CR284","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.kint.2018.05.025","volume":"94","author":"D Nakano","year":"2018","unstructured":"Nakano, D. & Nishiyama, A. A novel role of renin inhibitor in the complement cascade. Kidney Int. 94, 650\u2013652 (2018).","journal-title":"Kidney Int."},{"key":"634_CR285","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04183101 (2020)."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00634-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00634-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00634-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T15:51:09Z","timestamp":1673711469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00634-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":285,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1038\/s41577-021-00634-8","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"24 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}